ArticleEye (London, England)2026
Incidence and baseline predictors of discontinuation in DRCRnet studies.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveTo evaluate the incidence and baseline predictors of participant discontinuation in Diabetic Retinopathy Clinical Research Retina Network (DRCRnet) studies
methodsUsing the publicly available DRCRnet data, discontinuation rate and its 95% confidence intervals (95% CI) were calculated. Univariable and multivariable logistic regression models were used to assess predictors for participant discontinuation, including demographic, clinical, and study design characteristics, and within-study correlation was accounted for using generalised estimating equations.
resultsAmong 7353 participants (mean age 60 years, 48.0% female, 64.1% non-Hispanic (NH)-White, 17.8% NH-Black, 14.2% Hispanic), 1110 participants (15.1%, 95% CI 14.3-15.9%) discontinued study participation over a median 24-month follow-up. Multivariable analysis showed significantly higher risk of discontinuation among Hispanic (aOR 1.73, 95% CI 1.38-2.18) and NH-Black (aOR 1.36, 95% CI 1.14-1.62) participants, those with age <50 years (aOR 1.46, 95% CI 1.21-1.77), 50-59 years (aOR 1.26, 95% CI 1.05-1.51), or ≥70 years (aOR 1.20, 95% CI 1.03-1.39), participants with higher baseline HbA1c (aOR 1.09 per unit increase, 95% CI 1.06-1.12), or baseline blood pressure ≥140/90 mmHg (aOR 1.24, 95% CI 1.09-1.41), and those in studies with follow-up length 24 to <36 months (aOR 1.64, 95% CI 1.02-2.64) or 36 to 48 months (aOR 2.68, 95% CI 1.87-3.84).
conclusionsApproximately 15% of participants in the eligible DRCRnet studies discontinued participation. Racial and ethnic identity, age, glycaemic and blood pressure control, and study follow-up duration are significant predictors of participant discontinuation and should be considered when designing future studies.
Identifiers
42728351What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.